|
1
|
Flower DR: The lipocalin protein family:
structure and function. Biochem J. 318:1–14. 1996.
|
|
2
|
Di Carlo A: The enigmatic role of
lipocalin 2 in human cancer. The multifunctional protein neutrophil
gelatinase-associated lipocalin (NGAL) and its ambiguous role in
human neoplasias. Prevent Res. 2: View Article : Google Scholar
|
|
3
|
Triebel S, Bläser J, Reinke H and
Tschesche H: A 25 kDa alpha 2-microglobulin-related protein is a
component of the 125 kDa form of human gelatinase. FEBS Lett.
314:386–388. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
6
|
Yan L, Borregaard N, Kjeldsen L and Moses
MA; The high molecular weight urinary matrix metalloproteinase
(MMP) activity is a complex of gelatinase B/MMP and neutrophil
gelatinase-associated lipocalin (NGAL): Modulation of MMP-9
activity by NGAL. J Biol Chem. 276:37258–37265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Viau A, El Karoui K, Laouari D, Burtin M,
Nguyen C, Mori K, Pillebout E, Bertger T, Mak TW, Knebelmann B,
Friedlander G, Barasch J and Terzi F: Lipocalin 2 is essential for
chronic kidney disease progression in mice and humans. J Clin
Invest. 120:4065–4076. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chakraborty S, Kaur S, Guha S and Batra
SK: The multifaceted roles of neutrophil gelatinase associated
lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta.
1826:129–169. 2012.PubMed/NCBI
|
|
9
|
Bolignano D, Donato V, Coppolino G, Campo
S, Buemi A, Lacquaniti A and Buemi M: Neutrophil
gelatinase-associated lipocalin (NGAL) as a marker of kidney
damage. Am J Kidney Dis. 52:595–605. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cho H and Kim JH: Lipocalin2 expressions
correlate significantly with tumor differentiation in epithelial
ovarian cancer. J Histochem Cytochem. 57:513–521. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang HJ, He XJ, Ma YY, Jiang XT, Xia YJ,
Ye ZY, Zhao ZS and Tao HQ: Expression of neutrophil
gelatinase-associated lipocalin in gastric cancer: a potential
biomarker for prognosis and ancillary diagnostic test. Anat Rec
(Hoboken). 293:1855–1863. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Provatopoulou X, Gounaris A, Kalogera E,
Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I and
Zografos G: Circulating levels of matrix metalloproteinase-9
(MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and
their complex MMP-9/NGAL in breast cancer disease. BMC Cancer.
9:3902009. View Article : Google Scholar
|
|
13
|
Moniaux N, Chakraborty S, Yalniz M,
Gonzalez J, Shostrom VK, Standop J, Lele SM, Ouellette M, Pour PM,
Sasson AR, Brand RE, Hollingsworth MA, Jain M and Batra SK: Early
diagnosis of pancreatic cancer: neutrophil gelatinase-associated
lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J
Cancer. 98:1540–1547. 2008. View Article : Google Scholar
|
|
14
|
Sobin LH and Wittekind CH; International
Union Against Cancer (UICC): TNM Classification Of Malignant
Tumors. 6th edition. New York, NY: Wiley-Liss; pp. 193–195.
2002
|
|
15
|
Kashyap MK, Kumar A, Emelianenko N,
Kashyap A, Kaushik R, Huang R, Khullar M, Sharma SK, Singh SK,
Bhargave AK and Upadhyaya SK: Biochemical and molecular markers in
renal cell carcinoma: an update and future prospects. Biomarkers.
10:258–294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Carlo A: Matrix metalloproteinase-2 and
-9 in the sera and in the urine of human oncocytoma and renal cell
carcinoma. Oncol Rep. 28:1051–1056. 2012.PubMed/NCBI
|
|
17
|
Barresi V, Ieni A, Bolignano D, Magno C,
Buemi M and Barresi G: Neutrophil gelatinase-associated lipocalin
immunoexpression in renal tumors: Correlation with histotype and
histological grade. Oncol Rep. 24:305–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perrin C, Patard JJ, Jouan F, Collet N,
Théoleyre S, Edeline J, Zerrouki S, Laguerre B, Bellaud-Roturaud
MA, Rioux-Leclercq N and Vigneau C: The neutrophil
gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness
in clear cell renal carcinoma. Prog Urol. 21:851–858. 2011.In
French.
|
|
19
|
Porta C, Paglino C, De Amici M, Quaglini
S, Sacchi L, Imarisio I and Canipari C: Predictive value of
baseline serum vascular endothelial growth factor and neutrophil
gelatinase-associated lipocalin in advanced kidney cancer patients
receiving sunitinib. Kidney Int. 77:809–815. 2010. View Article : Google Scholar
|
|
20
|
Morrissey JJ, London AN, Lambert MC and
Kharasch ED: Sensitivity and specificity of urinary neutrophil
gelatinase-associated lipocalin and kidney injury molecule-1 for
the diagnosis of renal cell carcinoma. Am J Nephrol. 34:391–398.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernández CA, Yan L, Louis G, Yang J,
Kutok JL and Moses MA: The matrix metalloproteinase-9/neutrophil
gelatinase-associated lipocalin complex plays a role in breast
tumor growth and is present in the urine of breast cancer patients.
Clin Cancer Res. 11:5390–5395. 2005.
|
|
22
|
Roy R, Louis G, Loughlin KR, Wiederschain
D, Kilroy SM, Lamb CC, Zurakowski D and Moses MA: Tumor-specific
urinary matrix metalloproteinase fingerprinting: identification of
high molecular weight urinary matrix metalloproteinase species.
Clin Cancer Res. 14:6610–6617. 2008. View Article : Google Scholar
|
|
23
|
Smith ER, Zurakowski D, Saad A, Scott RM
and Moses MA: Urinary biomarkers predict brain tumor presence and
response to therapy. Clin Cancer Res. 14:2378–2386. 2008.
View Article : Google Scholar : PubMed/NCBI
|
